Navigation Links
Gut research yields new anti-cancer approach

ated proteins, alpha and beta tubulin, which pair up to form a chain and then wind into a helix. The current studies found that high-dose PPARgamma inhibitors reduced levels of alpha and beta tubulin by 60 to 70 percent. Also described in the publication are studies where PPARgamma inhibitors killed tumor cells in mice without causing significant toxicity. That provides at least the hope that the drug class may not be prohibitively toxic in humans, the researchers said. More formal toxicity studies are underway.

While PPARgamma inhibitors reduce tubulin levels, older anti-microtubule drug classes; Vinca alkaloids, taxanes (including Taxol) and epithiolones; interfere with microtubule dynamics. To play their role in tumor growth, microtubules must remain flexible. Taxol, for example, "freezes" tubulin subunits, making the cell skeleton rigid and unable to make the shape changes necessary for cell division. Brought to the market by Bristol-Myers Squibb in 1993, Taxol had annual sales of $1.6 billion at its peak in 2000.

Unfortunately, Taxol and other standard, anti-tubulin drugs failed in colorectal cancer clinical trials. Gut tumor cells have evolved to include "efflux" proteins that recognize standard chemotherapies as foreign, and "pump them out" of tumor cells. Even for breast and lung cancer, the tumor types for which Taxol is most used, nearly 100 percent of these tumors eventually become resistant, said Alok A. Khorana, M.D., assistant professor of Medicine at the Medical Center. In cells with more drug efflux pumps, Taxol is not effective (e.g. pancreas, liver and colon), he said.

High-dose PPARgamma inhibitors may overcome the limits of current treatment because the profile of molecules likely to be pumped out by drug efflux proteins is known, and at least one of the PPARgamma inhibitors does not match it. In addition, PPARgamma inhibitors do not bind to the standard tubulin-binding site that renders Taxol useless when binding s
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers

Post Your Comments:
(Date:11/8/2009)... The loss of a gene through deletion of genetic m...icant abnormalities in learning and behavior, said... of Medicine ( www.bcm.edu ) in a report that appe... , "This research goes about 95 percent of the w...f individuals to this gene," said Dr. Arthur L. Be...
(Date:11/6/2009)...wire/ -- Auburn Hills, MI-based Law Enforcement In...ts locker system and patent-pending Biometric Acce...t of Health and Human Services, National Institute...er system will support the NIH,s entire police for... medical research agency. The project is expected...
(Date:11/4/2009)...ntists are reluctant to officially endorse green t...es to grow about its protective effects, including...ntion Research , a journal of the American Associa...ction in oral cancer. , Vassiliki Papadimitrako...nt of Thoracic/Head and Neck Medical Oncology at t...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2New method may accelerate drug discovery for difficult diseases like Parkinsons 13002 1New method may accelerate drug discovery for difficult diseases like Parkinsons 13002 2New method may accelerate drug discovery for difficult diseases like Parkinsons 13002 3New method may accelerate drug discovery for difficult diseases like Parkinsons 13002 4Full Transcript of Pelosi Press Conference on Health Care Reform 51561 1Full Transcript of Pelosi Press Conference on Health Care Reform 51561 2Full Transcript of Pelosi Press Conference on Health Care Reform 51561 3Full Transcript of Pelosi Press Conference on Health Care Reform 51561 4Full Transcript of Pelosi Press Conference on Health Care Reform 51561 5Full Transcript of Pelosi Press Conference on Health Care Reform 51561 6Full Transcript of Pelosi Press Conference on Health Care Reform 51561 7Full Transcript of Pelosi Press Conference on Health Care Reform 51561 8Full Transcript of Pelosi Press Conference on Health Care Reform 51561 9Full Transcript of Pelosi Press Conference on Health Care Reform 51561 10Full Transcript of Pelosi Press Conference on Health Care Reform 51561 11Full Transcript of Pelosi Press Conference on Health Care Reform 51561 12Full Transcript of Pelosi Press Conference on Health Care Reform 51561 13Full Transcript of Pelosi Press Conference on Health Care Reform 51561 14Full Transcript of Pelosi Press Conference on Health Care Reform 51561 15Full Transcript of Pelosi Press Conference on Health Care Reform 51561 16Full Transcript of Pelosi Press Conference on Health Care Reform 51561 17Full Transcript of Pelosi Press Conference on Health Care Reform 51561 18TriWest Healthcare Alliance Awarded 5 Year 2416 Billion Healthcare Contract 51556 1TriWest Healthcare Alliance Awarded 5 Year 2416 Billion Healthcare Contract 51556 2
...are being slaughtered for their ivory at a pace un... took effect in 1989. But the public outcry that r...ity of Washington conservation biologist contends ...e giant mammals, plight. , The elephant death ra...ent a year based on recent studies, which is actua...
...d - Kiwifruit lovers can look forward to new, nove...ease this week of crucial genetic data which fruit...arieties with increased health properties and exci...ealand-based fruit science company HortResearch an...rch and Development Corporation Limited announced ...
...d a drug to achieve normal levels of blood sugar i...y high insulin levels. If this approach succeeds i...or children with congenital hyperinsulinism, a rar...hich insulin levels become dangerously high. , "T...or children with the most common type of congenita...
Other Biology News:Ivory poaching at critical levels: Elephants on path to extinction by 2020? 2Ivory poaching at critical levels: Elephants on path to extinction by 2020? 3Genetic data promises new future for kiwi fruit 2Genetic data promises new future for kiwi fruit 3Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3
(Date:11/6/2009)...D, Calif., Nov. 6 Intarcia Therape...ts ITCA 650 (DUROS® continuous delivery of ex...tes at the Ninth Annual Diabetes Technology Meetin...ewscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,... Via ITCA 650 Lowers Plasma Glucose, HbA1c and Red...
(Date:11/5/2009)...RSBURG, Md., Nov. 5 GenV...ncial results for the third quarter ended Septembe...lion ($0.04 per share) for the three months ended ...million ($0.08 per share) in the comparable quarte... 2009, GenVec,s net loss was $14.1 million ($0.15 ...
(Date:11/5/2009)...EGO, Nov. 5 Imagenetix, ...hat William Spencer, President and CEO of Imagenet...2nd annual LD MICRO Conference on Thursday, Decemb...Angeles. ,, About LD MICRO ,, LD MICRO is a ... finding undervalued companies in the micro-cap sp...
(Date:11/5/2009)... Neb., Nov. 5 Transgenom...d financial results for the quarter ended Septembe...esented in the tables that follow. ,, Third Qu...of $366,000 or $0.01 per share for the third quart...r $0.01 per share for the third quarter of 2008. ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...ALTHAM, Mass., Aug. 18 Logical Therapeutics, Inc....nt of medicines that treat,diseases associated wit...the successful completion of its Phase 1b randomiz...cs study of LT-NS001, the Company,s proprietary,na...m December, 2007,through July, 2008 in normal adul...
...AN DIEGO, Aug. 18 LifeVantage Corporation,(OTC Bu...e only product,clinically proven to slow the progr...pany,s President & CEO, David Brown, is featured i...Press Show., The interview gives viewers an overv...mpany,s latest press release., To view the cli...
...HILADELPHIA, Aug. 17 /Xinhua-PRNewswire/ -- WuXi A...ech (NYSE: WX ) in the U.S., has announced,the ap... of Operations and,Joseph Hughes, Ph.D. as Vice Pr...acility., (Logo: http://www.newscom.com/cgi-bin/...ith the company for nine years in roles of,increas...
Other Biology Technology:Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2[video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility 2
Smarter Fermentation System Controller for One Vessel from Major Science
...are specifically depleted of a single complement p..., the alternative and classical pathways are left ... detection and quantitation of hemolytically activ...used to assess complement activation in non-human ...
Dispensing Bins from Terra Universal, Inc.
Midgard Prec Current Source from Stoelting Co.
Biology Products: